Cellceutix Further Expands Its Senior Managment Team With the Addition of an Industry Veteran

BEVERLY, MA–(Marketwired – August 30, 2016) - Cellceutix Corporation (OTC: CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce today the addition of another senior executive to its management team. Jane Harness, MS, MP, has been appointed to the role of Vice President, Clinical Sciences and Portfolio Management.

This new hire comes two months after pharmaceutical executive, Arthur P. Bertolino, MD, PhD, MBA, joined Cellceutix as President and Chief Medical Officer.

Ms. Harness is a seasoned industry executive with over 20 years of experience in clinical drug development, which will significantly broaden Cellceutix’s management capabilities going forward.

Ms. Harness will direct all management aspects toward advancing the Company’s pipeline, with a particular focus on clinical trials. Ms. Harness has successfully led numerous teams in executing clinical studies both internationally and domestically. Her expertise spans early and late-phase therapeutic programs at both large pharma, such as Pfizer and Novartis, and at smaller specialty companies. She possesses extensive experience in the areas of Dermatology, as well as Inflammation and Immunology. Ms. Harness has also run clinical trials in other therapeutic areas and has provided key leadership in project management and strategy.

“I am extremely pleased that Jane has joined our senior management team and, by so doing, further validates the Company’s vision for success in developing its portfolio of first-in-class drug candidates,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix. “Now is the time for efficient execution of strategies that will help take Cellceutix to the next level in its clinical programs. The addition of Jane to our team is a key operational development toward achieving this end,” said Dr. Bertolino.

Leo Ehrlich, Chief Executive Officer, added, “We recognize the need for Cellceutix to supplement its ranks with accomplished pharmaceutical leaders in order to realize the full potential of our clinical pipeline. With the June 2016 hiring of Dr. Bertolino, followed by the recent employment of Jane, another talented and proven leader, we are establishing a solid foundation for major accomplishments in drug development.”